secwatch.observer — SEC 8-K summary
======================================

Issuer:     Terns Pharmaceuticals, Inc. (TERN)
CIK:        0001831363
Form:       8-K
Filed at:   2024-08-05T23:59:59+00:00
Accession:  0000950170-24-090761
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Terns Q2 net loss $22.7M; cash $225M; TERN-601 Ph1 data Sep, TERN-701 data Dec 2024
--------------------------------------------------------------------------------

- Net loss of $22.7M for Q2 2024 ($0.31/share) vs $17.9M ($0.25/share) in Q2 2023.
- Cash, equivalents and marketable securities $225.3M, expected to fund operations into 2026.
- Top-line Phase 1 data for oral GLP-1 TERN-601 (obesity) expected September 2024.
- Interim Phase 1 CARDINAL trial data for allosteric BCR-ABL TERN-701 (CML) expected December 2024.
- Appointed Elona Kogan as CLO; CFO search underway; Mark Vignola to serve through Jan 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1831363/000095017024090761/0000950170-24-090761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1831363/000095017024090761/tern-20240805.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-090761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer